首页> 美国卫生研究院文献>Toxicological Research >Stability Evaluation of National Reference Standards for Blood Products in Korea
【2h】

Stability Evaluation of National Reference Standards for Blood Products in Korea

机译:韩国血液制品国家参考标准的稳定性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

National reference standards (NRSs) for biologics are established through potency estimation by a multicenter joint study of standard materials used in the approval process for national lot release and quality control of vaccines, blood products, and other biologics. In this study, a stability evaluation was conducted to determine whether the potency of NRSs for six blood products was being maintained at a consistent level in Korea. The present study conducted real-time stability tests via in-vivo/in-vitro bioassay on NRSs for blood coagulation factor VIII concentrate (2nd standard), antithrombin concentrate, prekallikrein activator, anti-hepatitis B immunoglobulin, blood coagulation factor IX concentrate, and anti-tetanus human immunoglobulin, as well as a trend analysis using cumulative annual results. The real-time stability test results showed that the mean potency of six NRSs was all within the control limit. In the trend analysis, the potency of NRS for blood coagulation factor VIII concentrate (2nd standard) showed a decreasing trend, while the potency of all other products had been stably maintained. The present study confirmed that the mean potency of NRSs for six blood products had been stably maintained in Korea. The findings of the present study establish a foundation that can ensure the quality of NRSs for biologics in Korea, and it is expected to make a major contribution to the supply of high-quality biologics.
机译:国家生物制品国家参考标准(NRS)是通过效能评估来建立的,该研究是通过对用于疫苗,血液制品和其他生物制品的国家批批准和质量控制的批准过程中使用的标准材料进行多中心联合研究而建立的。在这项研究中,进行了稳定性评估,以确定在韩国,六种血液制品的NRS效力是否保持在恒定水平。本研究通过NRS的体内/体外生物测定对凝血因子VIII浓缩物(第二标准),抗凝血酶浓缩物,激肽释放酶原激活剂,抗乙型肝炎免疫球蛋白,凝血因子IX浓缩物和抗破伤风人免疫球蛋白,以及使用累积年度结果进行趋势分析。实时稳定性测试结果表明,六个NRS的平均效价均在控制范围内。在趋势分析中,NRS对凝血因子VIII浓缩液(第二标准)的效力呈下降趋势,而所有其他产品的效力均已稳定保持。本研究证实,在韩国,六种血液制品的NRS平均效价已稳定保持。本研究的发现为确保韩国生物制剂的NRS质量奠定了基础,并且有望为高质量生物制剂的供应做出重大贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号